Company intelligence / Profile preview
AbTis
Suwon-si, Gyeonggi-do, South Koreaabtis.co.kr ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lead asset AT‑211 targeting CLDN18.2 entering US/Korea phase I studies in solid tumors including gastric/pancreatic cancers Q1/Q22025; preclinically highly potent/stable vs competitors using proprietary linker tech.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Antibody-drug conjugatesImmune stimulating antibody conjugatesTherapeutic radiopharmaceuticalsPeptide drug conjugates
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Lonza – collaboration to integrate the AbClick® platform into Lonza’s bioconjugation toolbox for manufacturing novel bioconjugates/ADCsDong-A ST – parent company since acquisition in December 2023; strategic support and integration into Dong-A’s R&D ecosystem.
Beyond the preview
Go deeper on AbTis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AbTis.